DS-8201 was exerting its therapeutic efficacy by specifically killing HER2 expressing tumors and increasing tumor infiltrating dendritic cells, CD4+ and CD8+ T-cells in vivo [137, 138]. Here, ERBB2 is linked to neoplasm.